Abstract
In light of clinical uncertainty and the high acquisition costs of trastuzumab, we examined the value for money associated with concurrent or sequential trastuzumab in women with HER-2/neu-positive breast cancer with small node-negative tumours (T1bN0).
| Original language | English |
|---|---|
| Pages (from-to) | 1834-40 |
| Number of pages | 7 |
| Journal | Annals of Oncology |
| Volume | 24 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jul 2013 |
Keywords
- Adult
- Aged
- Aged 80 and over
- Antibodies, Monoclonal Humanized)
- Antineoplastic Agents
- Breast Neoplasms
- Chemotherapy (Adjuvant)
- Cost-Benefit Analysis
- Female
- Humans
- Middle Aged
- Models (Economic)
- Neoplasm Recurrence (Local)
- Neoplasm Staging
- Quality-Adjusted Life Years
- Receptor (ErbB-2)
- Risk
- Treatment Outcome
